No need to calculate “involved/ uninvolved FLC ratio” - the calculator does the math for you once you enter the absolute kappa lambda levels from the lab report.

Bookmark: mSMART guidelines for myeloma are now available to download as PowerPoint slides. For over 15 years mSMART guidelines have been used by thousands of clinicians around the world. Shaji Kumar Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Mayo Myeloma #MedTwitter msmart.org/mm-treatment-g…

UCH Parkview Medical center at ACP COLORADO CHAPTER uchealth

Happy Women's Day! Dr. Judith Graham Pool🩸

Representing #UCH Parkview Medical Center as a poster finalist for the abstract competition at the ACP National Conference 2024 in Boston. #acpnational #ACPIMPhysicians #IM2024 #ACP Special thanks to Doug Duffee for their constant support.

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma. #AJH Mayo Clinic Comprehensive Cancer Center 10 Tables; Algorithms Includes current data including trials published this month! #ASCO24 onlinelibrary.wiley.com/doi/10.1002/aj…

This was a great meeting and another step in our fight against cancer!

#weekend_review 1/7 Role of allogeneic stem cell transplantation in Ph+ve ALL? 🧵 👇🏽 #leusm #ALL Outcome of Ph+ve ALL has significantly improved with TKI combinations and not considered high risk disease anymore 👇🏽

Happy to share our paper describing the benefit in addition of Blinatumomab in Newly diagnosed MRD negative B cell ALL. Congratulations to all who were part of this cooperative effort! nejm.org/doi/full/10.10…

CU Cancer Center's Daniel Pollyea, MD, MS, has been honored by the Leukemia & Lymphoma Society (@llsusa) for his research on leukemia stem cells and his efforts to develop drugs that can target these cells, leading to impactful treatments ⬇️ news.cuanschutz.edu/cancer-center/…

My takeaways from our Heme Reports Menin session #leusm 1. Despite promising results of Menin-i (in a very tough to treat group of AML, i.e KMT2A-r) primary and acquired resistance remains and issue and is not limited to MEN1 mutations. We need to learn more. ❓ 2.

Just published JAMA our review on ET Don’t miss the podcast JAMA Mayo Clinic Hematology-Oncology Fellowship Mayo Clinic Internal Medicine Residency Rochester Nico Gagelmann Vincent Rajkumar #mpnsm Review: Essential Thrombocythemia jamanetwork.com/journals/jama/…

@ CDiNardo Naval Daver, M.D. Sanam Loghavi, MD صنم لغوی 🔬🧬 Tapan Kadia Jen Marvin-Peek, MD Mrinal Patnaik Fadi Haddad, MD Naveen Pemmaraju, MD Nicholas Short MD Vikram Mathews Danielle Hammond, MD Patrick Reville, MD, MPH Mahesh Swaminathan Gautam Borthakur G Garcia-Manero

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

UCHealth Parkview IM residency has opportunities for observerships. Join our educational meet and greet (TEAMS link below) This Friday 4/11 0700 AM USA mountain time. Discussing the opportunity and reviewing an approach to EKG interpretation. teams.microsoft.com/l/meetup-join/…

Ph 1b/2 trial of Aza-Ven-Magro in newly-diagnosed high-risk and R/R #AML: Clinical data & correlative analysis, published in Clinical Cancer Research doi.org/10.1158/1078-0… Unfortunately, the neg Ph3 ENHANCE trials terminates research w/ Magrolimab and likely anti-CD47 Rx in AML for now

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies ACS Journal Cancer doi.org/10.1002/cncr.3…

👉👉👉Our group’s new article led by Dr Hannah Goulart & Dr Tapan Kadia Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia AML acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… | ACS Journal Cancer MD Anderson Cancer Center #leusm #endcancer | Sanam Loghavi, MD صنم لغوی 🔬🧬

New in Leukemia Journal : Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors nature.com/articles/s4137… #leusm

👉👉👉Just out in AmericanJournalofHematology - our group’s new paper led by .Tapan Kadia & Hagop Kantarjian,MD || Ph2 study Results CPX-351+VEN for patients w/ R/R AML (n=33;44%2nd Salvage Tx or later;30%prior SCT:: ORR=46% w/CRc 39%) #leusm #endcancer | onlinelibrary.wiley.com/doi/10.1002/aj… | Sanam Loghavi, MD صنم لغوی 🔬🧬